3512. Adulteration and misbranding of Conjugens tablets and Conjugestoral
tablets (conjugated estrogens). U. S. v. 2 Bottles, etc. (and 1 other
seizure action). (F. D. C. Nos. 30767, 39872. Sample Nos. 23103-L,
23105-L.)
LIBELS FITTED :   March 8 and 27,1951, District of New Jersey.
ALLEGED SHIPMENT: On or about November 20 and 22 and December 4, 1950,
by Success Chemical Co., Inc., from Brooklyn, N. Y.
PRODUCT: 2 1,000-tablet bottles and 1 bottle containing 600 tablets of Con-
jugens-and. 1 1,000-tablet bottle of Conjugestoral at East Orange, N. J., and
1 bottle containing approximately 350 Conjugens tablets at Bloomfield, N. J.
Analyses of two samples taken from the shipments of Conjugens showed
the total amount of estrogens actually present in the samples to be equivalent
to 0.56 mg. and 0.78 mg., respectively, of sodium estrone sulfate per tablet.
Analysis of a sample of the Conjugestoral tablets showed the total amount
of estrogens actually present in the sample to be equivalent to 0.35 mg. of
sodium estrone sulfate per tablet.
ISABEL, IN PART: "Tablets Conjugens (Conjugated Estrogens) * * * Dis-
tributed by Success Chemical Co., Inc., Brooklyn, New York" and "Tablets
?Conjugestoral (Conjugated Estrogens) * * * Distributors Corby-Frank-
lin Associates   New York, N. Y."
NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the articles
differed from that which they were represented to possess, namely, 1.25 mg.
of estrogens in their- naturally occurring water-soluble conjugated form ex-
pressed as sodium estrone sulfate.
Misbranding, Section 502 (a), the label statement "Each tablet contains 1.25
mgm. of Estrogens in their naturally occurring water-soluble conjugated form
expressed as sodium estrone sulfate" was false and misleading as applied to
the articles, which contained less than the stated amount of estrogens.
DISPOSITION: July 11 and 12, 1951. Default decrees of condemnation. The
court ordered that the lot seized at Bloomfield be destroyed and that the lots
seized at East Orange be delivered to the Food and Drug Administration.